

# MARAPHARM

CSE:MDM FSE:2M0 OTCQB:MRPHF

Kelowna, British Columbia

[info@marapharm.com](mailto:info@marapharm.com) Telephone: 778-583-4476

## News Release

### October 3, 2016 - Marapharm creates a Management Advisory Group

Kelowna, British Columbia, Canada – October 3, 2016

Marapharm symbols: **Canada - CSE:MDM / Germany - FSE:2M0 / United States - OTCQB:MRPHF**

Marapharm Ventures Inc. ("Marapharm") is updating and modernizing its management with the addition of a Management Advisory Group "MAG", consisting of up to 5 members.

The purpose is to seek expertise and mentorship outside of Marapharm to add focus, meet with and encourage innovation. MAG will strengthen the operations of Marapharm in an economic manner, with input from experts in acquisitions, mergers, international financing, foreign markets, marketing, product development and sales techniques. MAG organizational structure encourages communication and involvement between all stakeholders. The board continues its mandate of providing direction to operations and corporate governance. MAG members will be provided stock options and or a monthly stipend. Marapharm CEO, Linda Sampson, is very supportive of adding the MAG level to Marapharm. Acknowledging Marapharm's potential, "it will be an innovative component to its management model".

Additionally, Marapharm has announced that it has created and staffed a division to deal exclusively with trademarks and patents related to and or has synergy with the cannabis industry. A trademark is a recognizable sign, word, design, or expression that identifies products or services while providing a corporate identity. Trademark names owned by Marapharm include Happy Start™ and Happy Clones™.

In the Canadian market "Marapharm" has been approved as trademark, application number 1,684,832. This milestone advances and enhances the development of the Marapharm brand within the cannabis space. Medical marijuana is legal in Canada and the Canadian Government has indicated its plans to legalize marijuana for recreational use.

Over two and a half years ago, Marapharm applied to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

#### **ABOUT MARAPHARM VENTURES INC.**

[www.marapharm.com](http://www.marapharm.com)

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website ([www.thecse.com](http://www.thecse.com)), the OTC website ([www.otcmarkets.com](http://www.otcmarkets.com)) and Sedar website ([www.sedar.com](http://www.sedar.com)) under the profile for Marapharm Ventures Inc.

#### **FOR FURTHER INFORMATION:**

[www.marapharm.com](http://www.marapharm.com) or Linda Sampson, CEO, 778-583-4476  
[info@marapharm.com](mailto:info@marapharm.com)

#### **STOCK EXCHANGES:**

*Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the*

*adequacy or accuracy of this release.*

**FORWARD - LOOKING STATEMENTS:**

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.